Navigation Links
Study Published in Molecular Therapy Shows that Immune Response to FANG™ Personalized Cancer Therapeutic Correlates with Prolonged Survival in Patients with Advanced Stage Cancer
Date:3/1/2012

DALLAS, March 1, 2012 /PRNewswire/ -- Today Gradalis, Inc., announced that FANG™, the company's tumor-based personalized cancer therapeutic, elicits a robust and lasting immune response, resulting in statistically-significant prolonged survival in patients with advanced stage disease. The Phase 1 study, published today in the Nature Publishing Group journal Molecular Therapy, showed that treatment with FANG significantly increased survival in patients with advanced stage cancer compared to patients who received other forms of treatment in this non-randomized study.

The study evaluated 46 patients with varying tumor types, including melanoma, colorectal, breast, ovarian and hepatocellular cancers. A personalized FANG vaccine was manufactured from tumors removed from 42 of the 46 patients, and 27 patients received one monthly dose of the vaccine for up to 12 months. Twenty-three of the 27 patients receiving FANG achieved stable disease within two months of dose initiation. Median survival for the FANG group was 554 days compared to 132 days for the group that did not receive FANG. (P<0.0001) The "no FANG" group included 18 patients who had vaccine made but did not receive injections due to progression of disease or pursuit of other treatment options. FANG was well tolerated by all patients, and there were no treatment-related serious adverse events.

"The pronounced survival benefit achieved by FANG in patients with multiple tumor types is quite remarkable, and randomized Phase 2 trials are currently underway verifying these results," said John Nemunaitis, M.D., executive medical director of the Mary Crowley Cancer Research Centers and chief medical officer and co-founder of Gradalis. "The benefit is likely attributed to the triad approach which is designed into the vaccine to maximize its effect.  FANG is not only manufactured using each individuals' tumor to assure exposure to the appropriate antigens, but it also activates  immune cells and  prevents production of proteins that tumors use to avoid detection by the immune system. I believe that this triad approach may one day make it possible to turn cancer into a manageable chronic disease for many patients."

Eighteen patients who received FANG were evaluated using enzyme-linked immunospot (ELISPOT) assays to determine the extent of their cellular immune response to the FANG vaccine. Positive ELISPOT responses at four months were demonstrated in nine of the 18 patients evaluated, and this response was correlated to survival benefit (p=0.025). Positive immune response to FANG is durable, as seven of the nine ELISPOT responders were still alive when the manuscript was accepted for publication, having survival up to 500 days since start of treatment.  Routine, post-treatment monitoring of this patient group reveals that these seven patients are still alive today with survival ranging from 464 to 940 days. 

"In this study, FANG has prolonged life for a number of patients with advanced stage cancer who otherwise had little or no other treatment options," said David Shanahan, president, CEO and co-founder of Gradalis. "This study suggests that FANG may be applicable to multiple types of advanced cancer and may ultimately provide new treatment options, even for patients who have late stage or aggressive cancer."

FANG is currently being evaluated in several Phase 2 studies in patients with advanced ovarian cancer, advanced melanoma and advanced colorectal cancer with liver metastases.  In addition, Gradalis has initiated a clinical program evaluating FANG in children with Ewing's sarcoma.

About FANG

The FANG vaccine is manufactured from a cell suspension derived from a marble-sized portion of a patient's tumor removed during surgery. A plasmid expressing a well-established immune activator, granulocyte macrophage colony stimulating factor (GMCSF), and Gradalis' proprietary bifunctional short hairpin RNA construct against furin is introduced into the cells by electroporation. Cells are then incubated overnight, irradiated, frozen, QC-tested and released.  Vaccine is shipped to the patient's clinic where doses are thawed and administered monthly by intradermal injection.  FANG manufacturing is a straightforward two-day cGMP process that is applicable to nearly all tumor types with no modification, and it does not require patients to undergo apheresis or other taxing treatment protocols beyond medically-indicated surgical tumor removal.

About Gradalis, Inc.

Gradalis, Inc. is a privately-held, fully-integrated biotechnology company based in Dallas, Texas that is focused on developing, manufacturing and commercializing drugs, vaccines, tools and diagnostics primarily in the area of cancer. The company has two primary platforms:  one focused on personalized autologous vaccines and the other focused on bifunctional short hairpin RNA delivered via a proprietary lipoplex system. Gradalis has its own state of the art GMP manufacturing facility along with high-skilled technical leadership and staff, as well as a strategic partnership with Mary Crowley Cancer Research Centers for early stage clinical development of Gradalis products.  More information on the Company and its programs can be found at www.gradalisinc.com.

 


'/>"/>
SOURCE Gradalis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BrainCells Inc. Announces the Successful Completion of the Single Ascending Dose Study With BCI-838 and the Initiation of the Multiple Ascending Dose Study
2. Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups
3. Study Links the Risk of Hypogonadism in Men to Long Acting Opioids in Patients Using Daily Opioid Therapy for Chronic Noncancer Pain
4. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
5. Preclinical Study Examines Use of nContacts Technology in Enabling a Percutaneous Device Approach to Epicardial Ablation
6. CHPA Responds to Prescription Mandate Cost Implications Outlined in Oklahoma Economic Impact Study
7. Medical Device Study Examines Use of Emerging Markets and Outsourcing for Clinical Activities
8. Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
9. Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC
10. Understand the Lessons Learned from the FDA QbD Pilot Programme - Case Study Merck Serono
11. SCOLR Pharmas Partner to Commence Bioequivalence Study of Ondansetron
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Express Scripts (NASDAQ: ... the World,s Most Admired Companies within the Health Care: Pharmacy and ... named one of the World,s Most Admired Companies," said Tim ... by the commitment and passion of our 26,000 employees to make ... serve." ...
(Date:2/16/2017)... 2017  Prescription pain medications provided by "physicians in ... for long-term opioid use to take hold," according to ... edition of The New England Journal of Medicine ... patients in acute pain than in almost any other ... president of the American College of Emergency Physicians. "The ...
(Date:2/16/2017)... BOULDER, Colo. , Feb. 16, 2017 /PRNewswire/ ... enterprise mobility solutions for the healthcare, retail, manufacturing ... independent research on the performance and symbology support ... smartphone with a dual-mode camera/barcode scanner. The study, ... in comparing the PIVOT:SC to two phones with ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... February 19, 2017 , ... ... healthcare, will join forces with Healthwise ® at HIMSS 2017 ... industry leader in evidence-based health education, technology and services, will demonstrate a voice-powered ...
(Date:2/18/2017)... ... February 17, 2017 , ... CONTACT:, Glenn ... Beverly Hills plastic surgeon Dr. Glenn Vallecillos experiments SculpSure, the hot, ... "Traditionally, plastic surgery has been centered around that idea that to achieve ones ...
(Date:2/17/2017)... ... ... Smiles by Seese is a comprehensive family dental practice located ... practice as a skilled and highly credentialed dentist who is qualified to perform a ... all ages with excellence in general, restorative, and cosmetic dentistry . Their services ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... (ISTS) brings its educational assistance management solution to the exhibit floor for the ... in Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 healthcare ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... been named a finalist in the 8th Annual DecisionHealth Platinum Awards in recognition ... system. Qualis Health’s work is recognized across multiple award categories, highlighting four of ...
Breaking Medicine News(10 mins):